Mesylate Apatinib Combined With Irinotecan in Treatment of Recurrent Small Cell Lung Cancer

NCT03651219 · clinicaltrials.gov ↗

PHASE3

Phase

UNKNOWN

Status

90

Enrollment

OTHER

Sponsor class

Conditions

Small Cell Lung Cancer

Interventions

DRUG: Apatinib
DRUG: Irinotecan

Sponsor

Beijing Chest Hospital

Collaborators

[object Object]